Value Demonstration: Local, National or Multinational Retrospective Chart Review Studies
|
|
- Oscar Taylor
- 6 years ago
- Views:
Transcription
1 Value Demonstration: Local, National or Multinational Retrospective Chart Review Studies Retrospective chart review designed to fulfill real-world evidentiary requirements Retrospective chart review studies are often warranted in the absence of suitable healthcare databases and other secondary sources of information. Chart review methodology can resolve database gaps and facilitate the rapid collection of clinical, safety, and healthcare utilisation data. This method results in tailored, international patient-level datasets that are ideally suited as inputs to a wide range of burden of illness, drug utilisation, safety, and health economic analyses. These studies enable you to: Delineate longitudinal patterns of care and resource utilisation profiles by sub-groups of interest that can be monetised in local currencies Evaluate relationships between patterns of care and clinical outcomes of interest Meet EMA or FDA drug utilisation and/or safety outcomes requirements such as Post Authorisation Safety Studies (PASS) Quantify and describe off-label medication use Evaluate the impact of EMA- or FDA-mandated RMPs and REMS Describe the real-world safety profile of marketed products Identify unmet clinical need Inform clinical trial and other prospective study designs through cohort characterisation and analyses of variability UBC is a partner centre of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) scientific network which is coordinated by the EMA. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.
2 Chart data may include the following alongside patient-level clinical outcomes data: Demographics Disease symptoms and co-morbidities Treatment and diagnostic history Medications prescribed Physician and emergency room visits Real-World Evidence and Research Needs Characterise patients and patterns of care Inform trial or registry design Hospitalisations by length of stay and location Diagnostic test results Procedures Safety outcomes Chart Review Opportunity Describe patient cohort and sub-groups of interest Characterise usual care treatment patterns Ensure results are void of the Hawthorne effect since data are retrospective Identify treatment pathways Quantify variability in patient characteristics and outcomes Support sample size calculations Identify unmet clinical need Describe burden of illness Identify gaps in care pathways Quantify resource utilisation (RU) and estimate costs of care Capture RU from medical charts so that local unit costs can be applied to estimate costs of care Quantify planned versus actual RU (i.e., drug doses prescribed versus received) Meet FDA/EMA Risk Evaluation and Management Strategy (REMS) evaluation requirements Evaluate effectiveness of RMP or REMS Document (in)appropriate medication use Collect clinical outcomes Collect patient-level data describing clinical outcomes (i.e., death, significant medical events) over time and by sub-group of interest Capture and characterise safety outcomes Collect data on adverse and serious adverse events (AEs/SAEs) and their severity and associated management
3 UBC Approach UBC provides a proven approach to the full-service design and conduct of global, multinational retrospective chart review studies. Specifically, UBC offers significant scientific, epidemiologic, and health economics and outcomes research expertise resulting in tailored chart review designs. Project teams are lead by project managers who utilise innovative and flexible project management techniques and approaches to successfully implement these studies. Our global team of clinical research associates (CRAs) and clinical site specialists (CSSs) have local language capabilities and experience liaising with centres. UBC regulatory and contract managers demonstrate in-depth knowledge of country-specific regulatory practices and legislation. UBC has a proprietary electronic data capture (EDC) system that is 21 CRF Part 11/EU Annex 11-compliant and has been developed and refined over time specifically for chart review studies. The UBC team has expertise in the design, implementation, monitoring, safety reporting, cleaning, statistical analysis, and dissemination of retrospective chart review data. The teams build from the following functional areas: Scientists in Value Demonstration, Safety, Epidemiology, Registries, and Risk Management Operations Data management Analytics and biostatistics Pharmacovigilance Custom software design Sample Design Overview Study Period Chart Review Initiation Eligibility Period Case 1 Case 2 Start Date Start Date End Date (Date of death) End Date (Date of chart study, initiation or x time post index event/dx/visit [e.g. 6 months]) Case 3 Start Date End Date (Lost to follow-up)
4 The UBC approach to designing and managing chart review studies ensures that each study is: Quality Controlled Practical and Convenient Efficient Consistent Designed to withstand rigor of scientific peer review Employs data validations at the point of data entry Enables scientifically valid chart sampling and disposition tracking Employs a remote monitoring model, thereby avoiding the need for on-site monitoring and oversight Facilitates site and data monitoring in real-time Permits a clean dataset within days of database closure Enables simultaneous data collection across multiple countries Employs a standard protocol and paper or electronic case report form (CRF) resulting in standardised local or multinational data Experience UBC has conducted chart review studies in more than 15 countries around the world. The studies have varied in scale from fewer than 10 sites to more than 300, with patient cohorts ranging from a few hundred to thousands. UBC s experience across therapeutic areas includes, but is not limited to, oncology, cardiovascular, renal and infectious diseases/disorders, intensive care populations, and orphan diseases. Studies have included evaluations of burden of illness, patterns and costs of care, mandated Drug Utilisation Studies (DUS), Post-Authorisation Safety Studies (PASS), and REMS evaluations. For more information on UBC s comprehensive services, us at: info@ubc.com Express Scripts Holding Company. All Rights Reserved. EU Headquarters Hammersmith Grove London, W6 7HA United Kingdom +44 (0) US Headquarters 920 Harvest Drive Suite 200 Blue Bell, PA
5 Clinical Development & Late Stage Research» Risk Management & Pharmacovigilance VALUE DEMONSTRATION: LOCAL, NATIONAL OR MULTINATIONAL RETROSPECTIVE CHART REVIEW STUDIES Retrospective Chart Review Studies Help Fulfill Real-world Evidentiary Requirements. *Blue indicates UBC Scientist.» Selected Recent Publications Payne KA, Stein D. Retrospective chart review studies: An old dog with some new tricks? PharmaPhorum. Dec 30, Payne KA, Stein D, Marshall L, Sohal J, Jersino J-M. Chart Toppers. Multinational chart reviews offer effective and efficient real-world data capture to support various evidence needs, representing both good science and pragmatic methodology. Int Clin Trials 2012: Shreay S, Desrosiers M-P, Corey-Lisle P, Payne KA. A retrospective study to evaluate the time burden associated with outpatient red blood cell transfusions indicated for anemia due to concomitantly administered chemotherapy in cancer patients. Supportive Care in Cancer Payne KA, Rofail D, Baladi JF, Viala M, Abetz L, Desrosiers MP, Lordan N, Ishak K, Proskorovsky I. Iron Chelation Therapy: Clinical Effectiveness, Economic Burden and Quality of Life of Patients with Iron Overload. Adv Ther August; 25(8): Payne KA, Desrosiers MP, Caro JJ, Baladi JF, Lordan N, Proskorovsky I, Ishak K, Rofail D. Clinical and Economic Burden of Infused Iron Chelation Therapy in the United States. Transfusion October; 47(10): info@ubc.com
6 Clinical Development & Late Stage Research» Risk Management & Pharmacovigilance VALUE DEMONSTRATION: LOCAL, NATIONAL OR MULTINATIONAL RETROSPECTIVE CHART REVIEWS Selected Sample Chart Review Study Abstracts and Presentations *Blue indicates UBC Scientist. Payne KA, Stein D. Retrospective chart review studies and safety reporting requirements: issues and considerations. DIA; March 25-27, 2014; Vienna. Stein D, Bassel M, Payne KA. Drug utilization and safety evaluations: lessons learned from multi-national retrospective chart review case studies. Canadian Association for Population Therapeutics (CAPT) Annual Conference; November 17-19, 2013; Toronto, Ontario. Desrosiers M-P, Lordan N, Reynolds MR, Robinson Jr DW, Payne KA. Using Retrospective Chart Review Methodology to Characterize Patients, Treatment Patterns and Resource Utilization in a Cohort of Patients with Multicentric Castleman s Disease. Canadian Association for Population Therapeutics (CAPT) Annual Conference; November 17-19, 2013, Toronto. Stein D, Joulain F, Usman Iqbal, Naoshy S, Muszbek N, Payne KA, Ferry D. Quality of life in patients with metastatic colorectal cancer (mcrc): A utilities study in the United Kingdom (UK) and the Netherlands. ISPOR 16th Annual European Congress; Nov 4-6, 2013; Dublin. Stein D, Sise C, Sherwood M, Mortimer Ö. Endotoxin-associated Sterile Peritonitis Observational Study (e-steps): Safety Findings. 29th International Conference on Pharmacopidemiology and Therapeutic Risk Management (ICPE); August 25-28, 2013, Montréal Convention Center, Montréal. Sise, C, Rutherford P, Kovács L, Konings S, Zimmerman J, Cramp H, Stein D. Endotoxin-associated sterile peritonitis observational study (e-steps) results. 50th ERA-EDTA 2013 Annual Congress; May 18-21, Istanbul. Payne KA, Stein D, Stemhagen A. Multi-national retrospective chart review studies: Lessons learned from application of methodology to international evaluations of burden of illness and drug utilization and safety. ISPOR 18th Annual International Meeting; May , New Orleans. Desrosiers M-P, Lordan N, Reynolds MR, Robinson Jr DW, Payne KA. Using chart review methods to characterize patients, treatment patterns and clinical outcomes in a cohort of patients with multi-centric Castleman s disease. ISPOR 18th Annual International Meeting; May , New Orleans. Rahaghi F.F, Ferrer G, Zhang, J, Massaro S, Boulanger L, Alas V, Benjamin N, Payne K, Desrosiers M-P. COPD treatment pattern difference between pulmonologists and primary care physicians. ATS, Corey-Lisle P, McGarvey N, Desrosiers M-P, Donahue E, Badre S, Hubbard S. Development of a multi-national cross-sectional study to determine disease burden of cancer patients suffering from anemia in usual care and their caregivers. ONS Conference, Payne KA, Neasham D. Drug Utilization Studies: Opportunities and Challenges. Late Phase Drug Development World December 6, London. Payne KA, Stein D, De Cock E. Retrospective multinational chart review studies of adverse and serious adverse events in Europe: opportunities and challenges. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE); August 23-26, CCIB Barcelona. Corey-Lisle P, Shreay S, Collins H, Payne KA, Desrosiers M-P. Retrospective study to evaluate the patient time burden associated with outpatient red blood cell transfusions in cancer patients receiving chemotherapy. MASCC 2012 International Symposium (Multinational Association of Supportive Care in Cancer); New York City; June 28-30, Payne KA, Wasiak R, Stein D, Chancellor J. Multi-national chart review studies in Europe: Opportunities and challenges. ISPOR 13th Annual European Congress; November 6-9, 2010; Prague. info@ubc.com
Retrospective Chart Review Studies
Retrospective Chart Review Studies Designed to fulfill requirements for real-world evidence Retrospective chart review studies are often needed in the absence of suitable healthcare databases and/or other
More informationPatient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force
5 May 2017 EMA/180341/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Patient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force EMA Initiative 1.
More informationReal World Evidence in Europe
Real World Evidence in Europe Jessamy Baird, RWE Director Madrid, 20 th October 2014. BEFORE I BEGIN; DISCLAIMERS: Dual perspective: Pharmaceutical: I work for Lilly, but this presentation represents my
More informationEuropean network of paediatric research (EnprEMA)
20 December 2010 EMA/770017/2010 Human Medicines Development and Evaluation Recognition criteria for self assessment The European Medicines Agency is tasked with developing a European paediatric network
More informationEuropean network of paediatric research (Enpr-EMA)
23 January 213 EMA/25452/213, Rev 1 Human Medicines Development and Evaluation Recognition criteria for self assessment The European Medicines Agency is tasked with developing a European paediatric network
More informationEuropean network of paediatric research (EnprEMA)
17 February 2012 EMA/77450/2012 Human Medicines Development and Evaluation Recognition criteria for self assessment The European Medicines Agency is tasked with developing a European paediatric network
More informationUse of disease registries for benefitrisk evaluation of medicines: A regulatory perspective. DIA Europe April Basel, Switzerland
Use of disease registries for benefitrisk evaluation of medicines: A regulatory perspective DIA Europe 2018-17-19 April Basel, Switzerland Presented by Xavier Kurz Head of Service Surveillance and Epidemiology
More informationThank you for joining ISMPP U today! The program will begin promptly at 11:00 am EST
Thank you for joining ISMPP U today! The program will begin promptly at 11:00 am EST ISMPP would like to thank the following Platinum Sponsors for their ongoing support of the society Today s Program Presenter
More informationCorporate Induction: Part 2
Corporate Induction: Part 2 Identification of preventable Adverse Drug Reactions from a regulatory perspective March 1 st 2013, EMA Workshop on Medication Errors Presented by Almath Spooner, Pharmacovigilance
More informationBackground and Issues. Aim of the Workshop Analysis Of Effectiveness And Costeffectiveness. Outline. Defining a Registry
Aim of the Workshop Analysis Of Effectiveness And Costeffectiveness In Patient Registries ISPOR 14th Annual International Meeting May, 2009 Provide practical guidance on suitable statistical approaches
More informationPatient Registries Initiative Background, Achievements, Next steps
Patient Registries Initiative Background, Achievements, Next steps 21 November 2017 ENCePP Plenary meeting Presented by Xavier Kurz, Surveillance & Epidemiology Service, European Medicines Agency An agency
More informationTargeted technology and data management solutions for observational studies
Targeted technology and data management solutions for observational studies August 18th 2016 Zia Haque Arshad Mohammed Copyright 2016 Quintiles Your Presenters Zia Haque Senior Director of Data Management,
More informationLessons from the EMA Patient Registries Initiative
Lessons from the EMA Patient Registries Initiative STAMP Commission Expert Group 8 th June 2018 Presented by Peter Arlett, with contributions from Patricia McGettigan and Jane Moseley Head of Pharmacovigilance
More informationIIS Sponsor Reference Guide
IIS Sponsor Reference Guide The IIS Portal is the global, single point of access for all IIS submissions Table of Contents Logging in 2 Registration. 2 Study Submission 3 Submission Questionnaire Details.
More informationMeasures of impact of pharmacovigilance processes (3.3)
Measures of impact of pharmacovigilance processes (3.3) Session 4 - Reports from breakout sessions: gaps and observations Workshop: Measuring the Impact of Pharmacovigilance Activities London, 5-6 December
More informationCompassionate Use Systems in the EU How to improve for early access to patients
Compassionate Use Systems in the EU How to improve for early access to patients Author: EFPIA* Date: 10/03/2016 * Version: Final Sabine Atzor, Valdelene Iglesias Langer, EFPIA Agenda 1. Early Access Schemes
More informationERN Assessment Manual for Applicants
Share. Care. Cure. ERN Assessment Manual for Applicants 3.- Operational Criteria for the Assessment of Networks An initiative of the Version 1.1 April 2016 History of changes Version Date Change Page 1.0
More informationWhy aren t we all using Real-World Evidence if it is so insightful and powerful? Because it is difficult to generate. Introducing E360 by IMS Health
PROBLEM Why aren t we all using Real-World Evidence if it is so insightful and powerful? Because it is difficult to generate. SOLUTION Introducing E360 by IMS Health E360 is a revolutionary technology
More informationEUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES
EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES 24 OCTOBER 2011 INTRODUCTION 1. THE EUROPEAN CONTEXT Centres of expertise (CE) and European Reference
More informationPOSTGRADUATE DIPLOMA/MSc IN PHARMACEUTICAL MEDICINE
POSTGRADUATE DIPLOMA/MSc IN PHARMACEUTICAL MEDICINE 2018/2020 University of Dublin, Trinity College Index Introduction... 1 Aims... 1 Intended Participants... 1 Course Structure... 2 Course Content and
More informationPOST-LAUNCH DEMANDS: Dr Thomas Lönngren ISPOR Content
POST-LAUNCH DEMANDS: HOW CAN A COMPANY BEST ADDRESS THE CHALLENGES AND OPPORTUNITIES PRESENTED BY THE NEW EU PHARMACOVIGILANCE REQUIREMENTS OF THE REGULATORS, THE ASSESSOR S NEED FOR REAL WORLD EVALUATION,
More informationCancer Drugs Fund. Managed Access Agreement. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Cancer Drugs Fund Managed Access Agreement Daratumumab monotherapy for treating relapsed and refractory multiple myeloma NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Cancer Drugs Fund Data Collection
More informationEvaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes
Evaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes 2 nd Adverse Event Reporting and Safety Strategies Summit December 8-9, 2015
More informationIMPROVING YOUR CLINICAL TRIAL & ENHANCING THE PATIENT EXPERIENCE
ebook IMPROVING YOUR CLINICAL TRIAL & ENHANCING THE PATIENT EXPERIENCE Applying a patient-centered approach to enhance clinical trial performance, improve data quality, and ensure safety and efficacy.
More informationEuropean Patients Academy (EUPATI) Update
European Patients Academy (EUPATI) Update EMA meeting with patient/consumer organisations 11 Dec 2013 Maria Mavris EURORDIS // EUPATI WP4 Co-Lead For patient-centric medicines R&D and to contribute to
More informationUK Renal Registry 20th Annual Report: Appendix A The UK Renal Registry Statement of Purpose
Nephron 2018;139(suppl1):287 292 DOI: 10.1159/000490970 Published online: July 11, 2018 UK Renal Registry 20th Annual Report: Appendix A The UK Renal Registry Statement of Purpose 1. Executive summary
More informationPFF Patient Registry Protocol Version 1.0 date 21 Jan 2016
PFF Patient Registry Protocol Version 1.0 date 21 Jan 2016 Contents SYNOPSIS...3 Background...4 Significance...4 OBJECTIVES & SPECIFIC AIMS...5 Objective...5 Specific Aims... 5 RESEARCH DESIGN AND METHODS...6
More informationSafeguarding public health. The New PV Legislation its Impact on PV & MI
Safeguarding public health The New PV Legislation its Impact on PV & MI Sarah Vaughan - MHRA PIPA 2013 Manager s Meeting 13 th February 2013 Content Scope of change Key areas - ADR reporting - DDPS to
More informationSEEKING PATIENT PERSPECTIVES IN CLINICAL TRIAL DESIGN AMY FROMENT, GLOBAL FEASIBILITY OPERATIONS DIR THE PATIENT S VOICE 2017
SEEKING PATIENT PERSPECTIVES IN CLINICAL TRIAL DESIGN AMY FROMENT, GLOBAL FEASIBILITY OPERATIONS DIR THE PATIENT S VOICE 2017 IMPORTANT CONTEXT As a biopharmaceutical business, Amgen is a commercial entity.
More information4. Hospital and community pharmacies
4. Hospital and community pharmacies As FIP is the international professional organisation of pharmacists, this paper emphasises the role of the pharmacist in ensuring and increasing patient safety. The
More information2018 Optional Special Interest Groups
2018 Optional Special Interest Groups Why Participate in Optional Roundtable Meetings? Focus on key improvement opportunities Identify exemplars across Australia and New Zealand Work with peers to improve
More informationSPECIAL PROJECT IN NON-METASTATIC CASTRATE RESISTANT PROSTATE CANCER
SPECIAL PROJECT IN NON-METASTATIC CASTRATE RESISTANT PROSTATE CANCER Part 1: Overview Information Participating Organization(s) Funding Opportunity Title Description Prostate Cancer Canada Special Project
More informationPAED-Net the German Network
PAED-Net the German Network Clinical Research in Paediatrics 2nd Symposium of the Swiss Clinical Trial Organisation 9th June, 2011, Basel Prof. Dr. Fred Zepp Department of Paediatrics University Medical
More informationUK Renal Registry 13th Annual Report (December 2010): Appendix A The UK Renal Registry Statement of Purpose
Nephron Clin Pract 2011;119(suppl 2):c275 c279 DOI: 10.1159/000331785 Published online: August 26, 2011 UK Renal Registry 13th Annual Report (December 2010): Appendix A The UK Renal Registry Statement
More informationTopic: CAP s Legislative Proposal for Laboratory-Developed Tests (LDT) Date: September 14, 2015
Topic: CAP s Legislative Proposal for Laboratory-Developed Tests (LDT) Date: September 14, 2015 1. What are the CAP s views on the regulatory oversight of laboratory-developed tests (LDTs)? 2. How are
More information1. Introduction, purpose of this Standard Operating Procedure (SOP)
SOP-CTN-001- Clinical Trial Network - General Organisation and Principles European Society of Anaesthesiology Details Document Type Document name Ref # Version Effective from Review date Owner Prepared
More information2017/18 and 2018/19 National Tariff Payment System Annex E: Guidance on currencies without national prices. NHS England and NHS Improvement
2017/18 and 2018/19 National Tariff Payment System Annex E: Guidance on currencies without national prices NHS England and NHS Improvement December 2016 Contents 1. Introduction... 3 2. Critical care adult
More informationSIMPLE SOLUTIONS. BIG IMPACT.
SIMPLE SOLUTIONS. BIG IMPACT. SIMPLE SOLUTIONS. BIG IMPACT. QUALITY IMPROVEMENT FOR INSTITUTIONS combines the American College of Cardiology s (ACC) proven quality improvement service solutions and its
More information1. Introduction, purpose of this Standard Operating Procedure (SOP)
Details Document Type Document name Ref # Version Effective from Review date Owner Prepared by Reviewed by Approved by Superseded documents Relevant regulations/legislation/guidelines/reference Standard
More informationPharmacovigilance Office of Product Review
Pharmacovigilance Office of Product Review Dr Jane Cook Office Head Office of Product Review, Monitoring & Compliance Group, TGA 7/10/2011 Overview of talk Overview Post TGA 21 and OPR New Guidelines Key
More informationModel of Care Scoring Guidelines CY October 8, 2015
Model of Care Guidelines CY 2017 October 8, 2015 Table of Contents Model of Care Guidelines Table of Contents MOC 1: Description of SNP Population (General Population)... 1 MOC 2: Care Coordination...
More informationType of intervention Secondary prevention of heart failure (HF)-related events in patients at risk of HF.
Emergency department observation of heart failure: preliminary analysis of safety and cost Storrow A B, Collins S P, Lyons M S, Wagoner L E, Gibler W B, Lindsell C J Record Status This is a critical abstract
More informationThe Role of the Agency for Healthcare Research and Quality (AHRQ) in the US Drug Safety System
The Role of the Agency for Healthcare Research and Quality (AHRQ) in the US Drug Safety System Scott R. Smith, MSPH, PhD Center for Outcomes & Evidence Agency for Healthcare Research & Quality July 20,
More informationEUCERD RECOMMENDATIONS on RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS)
EUCERD RECOMMENDATIONS on RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS) 31 January 2013 1 EUCERD RECOMMENDATIONS ON RARE DISEASE EUROPEAN REFERENCE NETWORKS (RD ERNS) INTRODUCTION 1. BACKGROUND TO
More informationRegistry of Patient Registries (RoPR) Policies and Procedures
Registry of Patient Registries (RoPR) Policies and Procedures Version 4.0 Task Order No. 7 Contract No. HHSA290200500351 Prepared by: DEcIDE Center Draft Submitted September 2, 2011 This information is
More informationUsing Electronic Health Records for Antibiotic Stewardship
Using Electronic Health Records for Antibiotic Stewardship STRENGTHEN YOUR LONG-TERM CARE STEWARDSHIP PROGRAM BY TRACKING AND REPORTING ELECTRONIC DATA Introduction Why Use Electronic Systems for Stewardship?
More informationAnalysis Group, Inc. Health Economics, Outcomes Research, and Epidemiology Practice Areas
Analysis Group, Inc. Health Economics, Outcomes Research, and Epidemiology Practice Areas September 13, 2012 BOSTON CHICAGO DALLAS DENVER LOS ANGELES MENLO PARK MONTREAL NEW YORK SAN FRANCISCO WASHINGTON
More informationUsing Real-World Data for Outcomes Research and Comparative Effectiveness Studies
Using Real-World Data for Outcomes Research and Comparative Effectiveness Studies Christina Mack, MSPH, PhD Director, Epidemiology and Health Outcomes, Quintiles Adjunct Assistant Professor, Epidemiology,
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Risk Assessment SOP-RES-002 Version Number 2 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s)
More informationMarie-Claire Rickard, RG and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager
Standard Operating Procedures (SOP) for: Pharmacovigilance processing for the JRMO SOP Number: 26c Version Number: V1 Effective Date: 5/8/16 Review Date: 5/8/17 Author: Reviewer: Reviewer: Authorisation:
More informationIMPACT OF RN HYPERTENSION PROTOCOL
1 IMPACT OF RN HYPERTENSION PROTOCOL Joyce Cheung, RN, Marie Kuzmack, RN Orange County Hypertension Team Kaiser Permanente, Orange County Joyce.m.cheung@kp.org and marie-aline.z.kuzmack@kp.org Cell phone:
More informationIntroduction to Health Economics and Outcomes Research (HEOR) for Writers
Introduction to Health Economics and Outcomes Research (HEOR) for Writers Beth Lesher, PharmD, BCPS Catherine O Connor, BA blesher@pharmerit.com coconnor@pharmerit.com Pharmerit International 4350 East
More informationMaking the most of patient registries
Making the most of patient registries Elizabeth Hernberg-Ståhl M.Sc. Stockholm October 15 Late Phase Solutions Europe AB Rare Disease Research Forum- Challenges and Solutions Stockholm KI, February 21,
More informationDPM Sampling, Study Design, and Calculation Methods. Table of Contents
DPM Sampling, Study Design, and Calculation Methods Table of Contents DPM Sampling, Study Design, and Calculation Methods... 1 Facility Sample Frame DOPPS 4 (2009-2011)... 2 Facility Sample Frame DOPPS
More informationConfronting the Challenges of Rare Disease:
Confronting the Challenges of Rare Disease: SOLUTIONS ACROSS THE ENTIRE PRODUCT LIFE CYCLE The Orphan Drug Act of 1983 brought increased awareness to the need for new treatments for rare disease patients
More informationUNIVERSITY OF WISCONSIN HOSPITAL AND CLINICS DEPARTMENT OF PHARMACY SCOPE OF PATIENT CARE SERVICES FY 2017 October 1 st, 2016
UNIVERSITY OF WISCONSIN HOSPITAL AND CLINICS DEPARTMENT OF PHARMACY SCOPE OF PATIENT CARE SERVICES FY 2017 October 1 st, 2016 Department Name: Department of Pharmacy Department Director: Steve Rough, MS,
More informationPharmacovigilance assessor. National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Senior hospital Pharmacist
Curriculum vitae PERSONAL INFORMATION Gyorgyi Fodor WORK EXPERIENCE September 2011 Present Pharmacovigilance assessor National Institute of Pharmacy and Nutrition (OGYÉI) (Hungary) Benefit/risk assessment,
More information3M Health Information Systems. 3M Clinical Risk Groups: Measuring risk, managing care
3M Health Information Systems 3M Clinical Risk Groups: Measuring risk, managing care 3M Clinical Risk Groups: Measuring risk, managing care Overview The 3M Clinical Risk Groups (CRGs) are a population
More informationMeasured Implementation of an Accelerated Chest Pain Diagnostic Pathway in Rural Practice. Proof of concept
Measured Implementation of an Accelerated Chest Pain Diagnostic Pathway in Rural Practice Proof of concept Authors Tim Norman Pinnacle Midlands Health Network Dr Jo Scott Jones - Pinnacle Midlands Health
More informationCOMMISSIONING SUPPORT PROGRAMME. Standard operating procedure
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE COMMISSIONING SUPPORT PROGRAMME Standard operating procedure April 2018 1. Introduction The Commissioning Support Programme (CSP) at NICE supports the
More informationPCORI s Approach to Patient Centered Outcomes Research
PCORI s Approach to Patient Centered Outcomes Research David H. Hickam, MD, MPH Director, PCORI Clinical Effectiveness and Decision Science Program Charleston, SC July 18, 2017 Goals of this Presentation
More informationPatients First Perspective on EMA relocation
Patients First Perspective on EMA relocation October 2017 Prepared by Fundación de Ciencias del Medicamento y Productos Sanitarios (FUNDAMED) Quality Departament and the Wecare-u Solutions Area. Coordination
More informationCurrent and future standardization issues in the e Health domain: Achieving interoperability. Executive Summary
Report from the CEN/ISSS e Health Standardization Focus Group Current and future standardization issues in the e Health domain: Achieving interoperability Executive Summary Final version 2005 03 01 This
More informationObjectives. Cancer Registry Abstracting
American American College College of of Surgeons 2013 Content 2014 Content cannot be be reproduced or or repurposed without written permission of of the the American College College of Surgeons. of Surgeons.
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Centre for Health Technology Evaluation
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Health Technology Evaluation Increasing capacity within Technology Appraisals Consultation comments proforma Name Role Organisation E-Mail Address
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationA Network of Long Term Care Facilities for Conducting Pharmaco-Epi Observational Studies: Experience from USA and Europe
A Network of Long Term Care Facilities for Conducting Pharmaco-Epi Observational Studies: Experience from USA and Europe Vincent Mor, Ph.D. Giovanni Gambassi, M.D. 1 Conflicts of Interest -- Mor F PI of
More informationRevisiting the inpatient rehabilitation case-mix and funding model in Ontario, Canada: lessons learned
Revisiting the inpatient rehabilitation case-mix and funding model in Ontario, Canada: lessons learned Kristen Pitzul, Emitis Moshirzadeh, Jan Walker, Kevin Yu, Sandro Serino, Imtiaz Daniel Quick Facts
More informationGuidance notes for patient safety and pharmacovigilance in patient support programmes
Guidance notes for patient safety and pharmacovigilance in patient support programmes Authors: The ABPI Pharmacovigilance Expert Network Version: 2.14 Date: March 2018 Acknowledgements: We thank the many
More information4. Multi Stakeholder: Late & Early Dialogue
4. Multi Stakeholder: Late & Early Dialogue Presented by Spiros Vamvakas on 19 September 2017 Head of Scientific Advice Office An agency of the European Union Background Starting point: Regulators and
More informationObjectives. Hospital Pharmacy Strategies for REMS. Evolution of FDA Drug Safety Programs. REMS: Definition. Evolution of FDA Drug Safety Programs
Objectives Hospital Pharmacy Strategies for REMS SCSHP Fall Meeting October 28, 2010 John Pearson, PharmD, BCNSP, BCPS Manager, Pharmacy Clinical Services Greenville Hospital System University Medical
More informationNew Alignments in Data-Driven Care Coordination & Access for Specialty Products: Insights from the DIMENSIONS Report
New Alignments in Data-Driven Care Coordination & Access for Specialty Products: Insights from the DIMENSIONS Report Our Objectives By the end of the session, participants will understand: Evolving demands
More informationValue Added Medicines Rethink, Reinvent & Optimize Medicines, Improving Patient Health & Access
Rethink, Reinvent & Optimize Medicines, Improving Patient Health & Access 09 June 2016 Pr. Mondher Toumi M.D., MSc., Ph.D. Professor in Public Health Department Research Unit EA 3279, Aix-Marseille University
More informationSetting The economic study was conducted in a large teaching hospital in Amsterdam, the Netherlands.
Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital Sevinc F, Prins J M, Koopmans R P, Langendijk P N, Bossuyt P M, Dankert J, Speelman P Record
More informationEffectiveness and safety of intravenous therapy at home for children and adolescents with acute and chronic illnesses: a systematic review protocol
Effectiveness and safety of intravenous therapy at home for children and adolescents with acute and chronic illnesses: a systematic review protocol Helena Hansson 1 Anne Brødsgaard 2 1 Department of Paediatric
More informationPHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK
PHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK 0 CONTENTS Course Description Period of Learning in Practice Summary of Competencies Guide to Assessing Competencies Page 2 3 10 14 Course
More informationClinical Trials at PMH
Clinical Trials at PMH What You Need To Know UHN Patient Education Improving Health Through Education A Guide for Patients, Their Families and Friends in the PMH Cancer Program This information is to be
More informationHMSA Physical and Occupational Therapy Utilization Management Guide
HMSA Physical and Occupational Therapy Utilization Management Guide Published November 1, 2010 An Independent Licensee of the Blue Cross and Blue Shield Association Landmark's provider materials are available
More informationAtrial Fibrillation Ablation Survey
Registries and surveys have been conducted in patients with AFib to determine the epidemiological aspects of the disease Background and rationale Atrial Fibrillation (AFib) is associated with a reduced
More informationJoint Statement on the Application of Good Clinical Practice to Training for Researchers
Joint Statement on the Application of Good Clinical Practice to Training for Researchers HRA, MHRA, Devolved Administrations for Northern Ireland, Scotland and Wales v1.1 12/10/17 Summary This joint statement
More informationo o o o o 2014 Application Form Congratulations, you have been selected to apply for the Lilly Innovation Fellowship Award. This is a competitive Award program designed to identify, recognize
More informationAMGEN S APPROACH TO VALUE- BASED HEALTHCARE IN EUROPE
AMGEN S APPROACH TO VALUE- BASED HEALTHCARE IN EUROPE HERB RIBAND VP INTERNATIONAL POLICY & GOVERNMENT AFFAIRS 16 OCTOBER 2017 TODAY S DISCUSSION FOCUSES ON THREE TOPICS 1. Mounting healthcare system pressures
More informationSafety Surveillance for Medical Devices
Safety Surveillance for Medical Devices May 10, 2012 James P. Keller, M.S. Vice President, Health Technology Evaluation and Safety jkeller@ecri.org (610) 825-6000, ext. 5279 Presentation Overview ECRI
More informationThe Development of the Oncology Symptom Management Clinic
The Development of the Oncology Symptom Management Clinic Submitted by: Catherine Brady-Copertino BSN, MS, OCN Executive Director Anne Arundel Medical Center s Geaton and JoAnn DeCesaris Cancer Institute
More informationFULL TEAM AHEAD: UNDERSTANDING THE UK NON-SURGICAL CANCER TREATMENTS WORKFORCE
FULL TEAM AHEAD: UNDERSTANDING THE UK NON-SURGICAL CANCER TREATMENTS WORKFORCE DECEMBER 2017 Publication date 04/12/17 Registered Charity in England and Wales (1089464), Scotland (SC041666) and the Isle
More informationThe PCT Guide to Applying the 10 High Impact Changes
The PCT Guide to Applying the 10 High Impact Changes This Guide has been produced by the NHS Modernisation Agency. For further information on the Agency or the 10 High Impact Changes please visit www.modern.nhs.uk
More informationClinical Research Professionals
Training & Resources for Clinical Research Professionals Course & Publications Catalog January July 2016 In-Person and Web-Based Training Courses, Customized Training, elearning and Publications for Clinical
More informationExperiences of using routinely collected medical data in a cardiovascular safety trial?
Experiences of using routinely collected medical data in a cardiovascular safety trial? Ian Ford Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit Issues in clinical trials Study feasibility
More informationProfessional Student Outcomes (PSOs) - the academic knowledge, skills, and attitudes that a pharmacy graduate should possess.
Professional Student Outcomes (PSOs) - the academic knowledge, skills, and attitudes that a pharmacy graduate should possess. Number Outcome SBA SBA-1 SBA-1.1 SBA-1.2 SBA-1.3 SBA-1.4 SBA-1.5 SBA-1.6 SBA-1.7
More informationWHO Programme for International Drug Monitoring, Pharmacovigilance Centres & Patient Safety
WHO Programme for International Drug Monitoring, Pharmacovigilance Centres & Patient Safety Birth of WHO Drug Monitoring Programme Thalidomide Phocomelia 2 16th World Health Assembly 1963 Assembly Resolution
More informationEuropean IVD Regulations and Risk Based Classification. An Overview for Global Quality Professionals
European IVD Regulations and Risk Based Classification An Overview for Global Quality Professionals Anna Sadio IVD Technical Expert/Project Manager Oct 2013 Caution The new regulations are draft and subject
More informationNATIONAL HEALTH SERVICE, ENGLAND
D I R E C T I O N S NATIONAL HEALTH SERVICE, ENGLAND The Health and Social Care Information Centre (Establishment of Information Systems for NHS Services: Data Services for Commissioners) Directions 2013
More informationDraft 2014 CMS Advanced Notice and Call Letter to Medicare Advantage and Part D Prescription Drug Plans
Jonathan Blum Center for Medicare Center for Medicare and Medicaid Services Hubert H. Humphrey Building 200 Independence Avenue, SW, MS:314G Washington, DC 20201 [Submitted electronically to: AdvanceNotice2014@cms.hhs.gov]
More informationPhysician / Investigator. Over 40% of clinical trial data are entered into health record and EDC 1
EHR4CR AN INNOVATIVE PLATFORM AND BUSINESS MODEL ACDM Annual Conference, 9 Richard Perkins, eclinical Forum Electronic Health Records for Clinical Research 1 Industry-centric growth in ICT 57% of R&D investment
More informationChapter 4 Health Care Management Unit 5: Quality Management
Chapter 4 Health Care Management Unit 5: Quality Management In This Unit Topic See Page Unit 5: Quality Management Quality Management Program 2 Prevention and Wellness 4 Clinical Quality 5 Network Quality
More informationMeasuring and reporting outcomes in wound care: The standardization conundrum creating a new framework to define quality wound healing
Measuring and reporting outcomes in wound care: The standardization conundrum creating a new framework to define quality wound healing As the nation s largest provider of advanced wound care services,
More informationJH-CERSI/FDA Workshop Clinical Trials: Assessing Safety and Efficacy for a Diverse Population
JH-CERSI/FDA Workshop Clinical Trials: Assessing Safety and Efficacy for a Diverse Population Use of Epidemiologic Studies to Examine Safety in Diverse Populations Judy A. Staffa, Ph.D, R.Ph. Director
More informationUNDERSTANDING THE CONTENT OUTLINE/CLASSIFICATION SYSTEM
BOARD OF PHARMACY SPECIALTIES PSYCHIATRIC PHARMACY SPECIALIST CERTIFICATION CONTENT OUTLINE/CLASSIFICATION SYSTEM FINALIZED FEBRUARY 2017/FOR USE ON FALL 2017 EXAMINATION AND FORWARD UNDERSTANDING THE
More informationComparison of Care in Hospital Outpatient Departments and Physician Offices
Comparison of Care in Hospital Outpatient Departments and Physician Offices Final Report Prepared for: American Hospital Association February 2015 Berna Demiralp, PhD Delia Belausteguigoitia Qian Zhang,
More informationCapturing the value of SCOPE to the EU Flagship Event London, 23 November 2016
Capturing the value of SCOPE to the EU Flagship Event London, 23 November 2016 Helen Lee European Commission, Health and Food Safety Directorate General Outline of the presentation Characterisitics of
More information